Nasdaq

QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug Administration ...
Business Wire

GENECAST Launches BRAF Mutation Test Kits with the Highest Detection Sensitivity 0.0001%

Assures 100x upgraded detection sensitivity compare to ddPCR Higher the possibility of precision medicine in the 1st and 2nd stages of cancer patients SEOUL, South Korea--(BUSINESS WIRE)--GENECAST, ...
Cancer Network

KRAS/BRAF Testing May Help Define Stage III Colon Cancer Prognosis

Survival following relapse appears to be shorter in patients with stage III colon cancer harboring KRAS exon 2 and BRAF V600E mutations regardless of microsatellite stability status. “We demonstrated ...
Medical Xpress

KRAS and BRAF mutation screening in metastatic colorectal cancer costly in relation to benefits

Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according ...
BIOENGINEER

Virtual Tumors Point to New Drug Combinations for Hard-to-Treat Lung Cancer Mutations

A new quantitative systems pharmacology model spanning all three classes of BRAF-mutant lung cancer predicts that MEK-ERK ...
ascopubs.org

Evolution of BRAF gene mutation testing and treatment options in BRAF mutation carriers in Canada.

BRAF exon 15 (7q34) mutation heterogeneity in metastatic and primary melanomas. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not include a full text ...
ascopubs.org

Turnaround Times in Melanoma BRAF Testing and the Impact on the Initiation of Systemic Therapy at a Single Tertiary Care Cancer Center

This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the transfer time, which can be streamlined by pathology reflex testing. Delays in TAT affect the timing ...
FierceBiotech

Labcorp nabs FDA green light for BRAF melanoma diagnostic

Around half of all cutaneous melanomas carry a BRAF mutation, with the majority of these being V600E. (Nasekom/iStock/Getty Images Plus) The FDA has signed off on Labcorp’s companion diagnostic for ...
Medscape

The Diagnostic Role and Clinical Relevance of Determination of BRAF Status in Brain Tumors

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...
FiercePharma

Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers

"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...
streetinsider

Qiagen (QGEN) Launches Therascreen BRAF Test as Companion Diagnostic to BRAFTOVI Based Regimen in Metastatic Colorectal Cancer

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. QIAGEN N.V. (NYSE: QGEN) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF ...